José Carlos Arévalo-Lorido1, Juana Carretero Gómez2, Ricardo Gómez Huelgas3, Dolores García de Lucas4, Lourdes Mateos Polo5, José Manuel Varela Aguilar6, Javier Ena Muñoz7. 1. Internal Medicine Department, Zafra County Hospital, Ctra Badajoz-Granada s/n, 06300, Zafra, Badajoz, Spain. joscarlor@gmail.com. 2. Internal Medicine Department, Zafra County Hospital, Ctra Badajoz-Granada s/n, 06300, Zafra, Badajoz, Spain. 3. Internal Medicine Department, University Hospital of Málaga, Avda de Carlos Haya, s/n, 29010, Málaga, Spain. 4. Internal Medicine Department, "Costa del sol" Hospital, Autovía A7, Km 187, 29603, Marbella, Málaga, Spain. 5. Internal Medicine Department, University Hospital of Salamanca, Paseo de San Vicente 182, 37007, Salamanca, Spain. 6. Internal Medicine Department, University Hospital "Virgen del Rocio", Av. Manuel Siurot, s/n, 41013, Sevilla, Spain. 7. Internal Medicine Department, "Marina Baixa" Hospital, Avda, Alcalde En Jaume Botella Mayor, s/n, 03570, La Vila Joiosa, Alicante, Spain.
Abstract
INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) often have numerous cardiovascular risk factors, among which hypertension. AIM: To evaluate the blood pressure variations among patients treated with a combination of a sodium-glucose cotransporter 2 inhibitor (iSGLT-2) and a glucagon-like peptide-1 receptor agonist (GLP-1ra). METHODS: We analyze 17 patients treated with this combination to quantify the changes on blood pressure by ambulatory blood pressure monitoring at baseline and at three and 6 months follow-up. RESULTS: We observed a decrease of HbA1c levels (p = 0.004) at six months follow-up, a decrease in mean 24 h systolic blood pressure [from 124 (11) mmHg to 123 (4.75) mmHg, p = 0.04] and in both, mean waking and sleeping systolic blood pressure, being greater the reduction in the sleeping time [118 (20) mmHg to 111 (20) mmHg, p = 0.004]. CONCLUSION: The effect of a combination therapy of an iSGLT-2 and a GLP-1ra on blood pressure in a real-world setting, may have summative effects especially in SBP.
INTRODUCTION:Patients with type 2 diabetes mellitus (T2DM) often have numerous cardiovascular risk factors, among which hypertension. AIM: To evaluate the blood pressure variations among patients treated with a combination of a sodium-glucose cotransporter 2 inhibitor (iSGLT-2) and a glucagon-like peptide-1 receptor agonist (GLP-1ra). METHODS: We analyze 17 patients treated with this combination to quantify the changes on blood pressure by ambulatory blood pressure monitoring at baseline and at three and 6 months follow-up. RESULTS: We observed a decrease of HbA1c levels (p = 0.004) at six months follow-up, a decrease in mean 24 h systolic blood pressure [from 124 (11) mmHg to 123 (4.75) mmHg, p = 0.04] and in both, mean waking and sleeping systolic blood pressure, being greater the reduction in the sleeping time [118 (20) mmHg to 111 (20) mmHg, p = 0.004]. CONCLUSION: The effect of a combination therapy of an iSGLT-2 and a GLP-1ra on blood pressure in a real-world setting, may have summative effects especially in SBP.
Authors: Vivian A Fonseca; J Hans Devries; Robert R Henry; Morten Donsmark; Henrik F Thomsen; Jorge Plutzky Journal: J Diabetes Complications Date: 2014-01-21 Impact factor: 2.852
Authors: Ilkka Tikkanen; Kirsi Narko; Cordula Zeller; Alexandra Green; Afshin Salsali; Uli C Broedl; Hans J Woerle Journal: Diabetes Care Date: 2014-09-30 Impact factor: 19.112
Authors: Keith C Ferdinand; William B White; David A Calhoun; Eva M Lonn; Philip T Sager; Rocco Brunelle; Honghua H Jiang; Rebecca J Threlkeld; Kenneth E Robertson; Mary Jane Geiger Journal: Hypertension Date: 2014-06-30 Impact factor: 10.190
Authors: Preman Kumarathurai; Christian Anholm; Andreas Fabricius-Bjerre; Olav W Nielsen; Ole Kristiansen; Sten Madsbad; Steen B Haugaard; Ahmad Sajadieh Journal: J Hypertens Date: 2017-05 Impact factor: 4.844
Authors: A R Kiselev; O M Posnenkova; O A Belova; S V Romanchuk; Y V Popova; M D Prokhorov; V I Gridnev Journal: High Blood Press Cardiovasc Prev Date: 2017-08-30
Authors: Bernhard Ludvik; Juan P Frías; Francisco J Tinahones; Julio Wainstein; Honghua Jiang; Kenneth E Robertson; Luis-Emilio García-Pérez; D Bradley Woodward; Zvonko Milicevic Journal: Lancet Diabetes Endocrinol Date: 2018-02-23 Impact factor: 32.069
Authors: Per Lundkvist; Maria J Pereira; Petros Katsogiannos; C David Sjöström; Eva Johnsson; Jan W Eriksson Journal: Diabetes Obes Metab Date: 2017-05-31 Impact factor: 6.577
Authors: Raymond R Townsend; Israel Machin; Jimmy Ren; Angelina Trujillo; Masato Kawaguchi; Ujjwala Vijapurkar; Chandrasekharrao V Damaraju; Michael Pfeifer Journal: J Clin Hypertens (Greenwich) Date: 2015-12-10 Impact factor: 3.738
Authors: Alessandra Saldanha de Mattos Matheus; Lucianne Righeti Monteiro Tannus; Roberta Arnoldi Cobas; Catia C Sousa Palma; Carlos Antonio Negrato; Marilia de Brito Gomes Journal: Int J Hypertens Date: 2013-03-04 Impact factor: 2.420